JP2008538183A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538183A5
JP2008538183A5 JP2008504533A JP2008504533A JP2008538183A5 JP 2008538183 A5 JP2008538183 A5 JP 2008538183A5 JP 2008504533 A JP2008504533 A JP 2008504533A JP 2008504533 A JP2008504533 A JP 2008504533A JP 2008538183 A5 JP2008538183 A5 JP 2008538183A5
Authority
JP
Japan
Prior art keywords
polypeptide
nucleic acid
seq
antibody
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008504533A
Other languages
English (en)
Other versions
JP2008538183A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/012606 external-priority patent/WO2006110413A2/en
Publication of JP2008538183A publication Critical patent/JP2008538183A/ja
Publication of JP2008538183A5 publication Critical patent/JP2008538183A5/ja
Pending legal-status Critical Current

Links

Claims (18)

  1. 配列番号:
    Figure 2008538183

    Figure 2008538183

    Figure 2008538183

    のうちの1つ以上に対して少なくとも75%の配列同一性を有するアミノ酸配列を含む、
    ポリペプチド。
  2. 配列番号:
    Figure 2008538183

    Figure 2008538183

    Figure 2008538183

    のアミノ酸配列のうちの1つ以上を含む、請求項1に記載のポリペプチド。
  3. 配列番号:
    Figure 2008538183

    Figure 2008538183

    Figure 2008538183

    Figure 2008538183

    のうちの1つ以上に由来する少なくとも7個の連続するアミノ酸のフラグメントを含む、
    ポリペプチド。
  4. 前記フラグメントが前記配列番号のアミノ酸配列由来のT細胞またはB細胞エピトープを
    含む、請求項3に記載のポリペプチド。
  5. 請求項1〜4のいずれか1項に記載のポリペプチドに結合する、抗体。
  6. モノクローナル抗体である、請求項5に記載の抗体。
  7. 配列番号:
    Figure 2008538183

    Figure 2008538183

    Figure 2008538183

    のうちの1つ以上に対して少なくとも75%の配列同一性を有するヌクレオチド配列を含
    む、核酸。
  8. 配列番号:
    Figure 2008538183

    Figure 2008538183

    Figure 2008538183

    から選択されるヌクレオチド配列を含む、請求項7に記載の核酸。
  9. 高いストリンジェンシーの条件下で、請求項8に記載の核酸にハイブリダイズし得る、核
    酸。
  10. 配列番号:
    Figure 2008538183

    Figure 2008538183

    Figure 2008538183

    Figure 2008538183

    のうちの1つ以上に由来する、10個またはそれより多い連続するヌクレオチドのフラグ
    メントを含む、核酸。
  11. 請求項1〜4のいずれか1項に記載のポリペプチドをコードする、核酸。
  12. (a)請求項1〜11のいずれか1項に記載のポリペプチド、抗体および/または核酸と

    (b)薬学的に受容可能なキャリアと
    を含む、組成物。
  13. ワクチンアジュバントをさらに含む、請求項12に記載の組成物。
  14. 医薬としての使用のための、請求項1〜11のいずれか1項に記載の核酸、ポリペプチド
    、または抗体。
  15. 患者を処置するための、請求項12に記載の組成物。
  16. インフルエンザ菌(Haemophilus influenzae)によって引き起こ
    される疾患および/または感染を処置または予防するための医薬の製造における、請求項
    1〜11のいずれか1項に記載の核酸、ポリペプチド、または抗体の使用。
  17. 細菌性髄膜炎を予防するための、請求項15に記載の組成物。
  18. 細菌性髄膜炎を予防するための、請求項16に記載の使用。
JP2008504533A 2005-03-30 2006-03-30 B型インフルエンザ菌 Pending JP2008538183A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66792105P 2005-03-30 2005-03-30
PCT/US2006/012606 WO2006110413A2 (en) 2005-03-30 2006-03-30 Haemophilus influenzae type b

Publications (2)

Publication Number Publication Date
JP2008538183A JP2008538183A (ja) 2008-10-16
JP2008538183A5 true JP2008538183A5 (ja) 2009-05-14

Family

ID=37087506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008504533A Pending JP2008538183A (ja) 2005-03-30 2006-03-30 B型インフルエンザ菌

Country Status (11)

Country Link
US (4) US20100034822A1 (ja)
EP (1) EP1871888A4 (ja)
JP (1) JP2008538183A (ja)
CN (1) CN101687025A (ja)
AU (1) AU2006235045A1 (ja)
BR (1) BRPI0609460A2 (ja)
CA (1) CA2602665A1 (ja)
MX (1) MX2007012057A (ja)
NZ (2) NZ591415A (ja)
RU (1) RU2007139915A (ja)
WO (1) WO2006110413A2 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
EP2590626B1 (en) 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomes with lipids having an advantageous pka-value for rna delivery
PT2590676T (pt) 2010-07-06 2016-11-04 Glaxosmithkline Biologicals Sa Partículas de transferência de tipo virião para moléculas de arn auto-replicante
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
PL3981427T3 (pl) 2010-08-31 2022-09-19 Glaxosmithkline Biologicals S.A. Pegylowane liposomy do dostarczania rna kodującego immunogen
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
EP2707024A4 (en) * 2011-05-11 2015-03-04 Riesbeck Healthcare Sweden Ab PROTEIN F - A NEW HAEMOPHILUS INFLUENZAE ADHESINE WITH LAMININ AND VITRONECTIN BINDING CHARACTERISTICS
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
JP2014520806A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー Rna分子の送達のための有用なn:p比を有するリポソーム
SG10201602456WA (en) 2011-08-31 2016-04-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
AR090303A1 (es) * 2013-03-11 2014-11-05 Consejo Nac Invest Cient Tec Polipeptido mutado, cepa de bacterias que lo comprende y metodos para detectar diferentes cationes metalicos simultaneamente
US9868777B2 (en) 2013-06-10 2018-01-16 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
WO2015095346A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2774968T3 (es) 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
ES2949172T3 (es) 2014-07-16 2023-09-26 Novartis Ag Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas
WO2016037053A1 (en) 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
GB201508860D0 (en) 2015-05-22 2015-07-01 Nat Univ Ireland Diagnostic method
US11401520B2 (en) 2016-10-21 2022-08-02 The Research Foundation For The State University Of New York Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB2599573A (en) * 2019-05-31 2022-04-06 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins
US11357845B2 (en) * 2019-07-08 2022-06-14 The Trustees Of The University Of Pennsylvania Protein antigens for vaccinating against nontypeable Haemophilus influenzae
EP4237577A1 (en) * 2020-10-30 2023-09-06 Gen-Probe Incorporated Compositions and methods for detecting influenza a, influenza b, and sars-cov-2
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
EP4387596A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Low-dose lyophilized rna vaccines and methods for preparing and using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355450B1 (en) * 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
US6730827B1 (en) * 1998-07-14 2004-05-04 E. I. Du Pont De Nemours And Company Genes encoding plant adenosine 5′-phosphosulfate reductase
US7365185B2 (en) * 2000-07-19 2008-04-29 Monsanto Technology Llc Genomic plant sequences and uses thereof
CA2404260A1 (en) * 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2004078949A2 (en) * 2003-03-06 2004-09-16 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae
GB0315022D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Virulence-associated adhesins
GB0410866D0 (en) * 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP1899366A2 (en) * 2005-06-16 2008-03-19 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae

Similar Documents

Publication Publication Date Title
JP2008538183A5 (ja)
JP2008525033A5 (ja)
RU2007139915A (ru) Haemophilus influenzae типа в
JP2010166916A5 (ja)
JP2012000112A5 (ja)
RU2006144093A (ru) Полипептиды нетипируемой haemophilus influenzae
JP2008529558A5 (ja)
JP2003527079A5 (ja)
JP2011004753A5 (ja)
JP2008508859A5 (ja)
JP2010273685A5 (ja)
RU2009102815A (ru) Полипептиды из neisseria meningitidis
JP2005511076A5 (ja)
JP2002531129A5 (ja)
JP2017507181A5 (ja)
JP2002542827A5 (ja)
JP2012522010A5 (ja)
JP2007502101A5 (ja)
EP2292648A3 (en) Small Streptococcus pyogenes antigens and their use
JP2015514132A5 (ja)
JP2010532657A5 (ja)
JP2006158399A5 (ja) 細胞増殖抑制タンパク質並びにそれを用いる細胞増殖抑制剤、癌診断薬及び癌治療剤
JP2012515557A5 (ja)
JP2010508276A5 (ja)
JP2004531242A5 (ja)